MRI检测乳头状肾细胞癌的诊断准确性:系统综述与Meta分析
该系统综述与Meta分析纳入13项研究,涉及275个乳头状肾细胞癌病灶和758个其他肾脏肿块,评估MRI鉴别乳头状肾细胞癌与其他肾脏病变的诊断性能。汇总敏感度为79.6%(95%CI 62.3-90.2%),特异度为88.1%(95%CI 80.1-93.1%)。亚组分析显示皮髓质期定量强化池化敏感度85.6%、特异度91.7%、SROC曲线下面积0.894;T2加权成像肿瘤表现池化敏感度89.9%、特异度84.9%。结论支持皮髓质期定量强化具有中等敏感度和极好特异度,联合强化与T2信号特征准确性有待进一步评估。
要点
- MRI鉴别乳头状肾细胞癌与其他肾脏病变汇总敏感度79.6%、特异度88.1%。
- 皮髓质期定量强化亚组SROC曲线下面积0.894,敏感度85.6%、特异度91.7%。
- T2加权成像肿瘤表现亚组敏感度89.9%、特异度84.9%。
核心结论
- Meta分析支持皮髓质期定量强化鉴别乳头状肾细胞癌与其他肿瘤具有中等敏感度和极好特异度;联合强化与T2信号强度特征的准确性有待进一步评估,可能作为管理决策的潜在辅助手段。
研究设计与样本
- 系统综述与Meta分析,检索三个电子数据库,纳入13项使用MRI技术鉴别乳头状肾细胞癌与其他肾脏病变的研究,涉及275个乳头状肾细胞癌病灶和758个其他肾脏肿块,采用双变量随机效应模型或构建汇总ROC曲线汇总诊断试验准确性。
关键影像表现/征象
- MRI鉴别乳头状肾细胞癌与其他肾脏病变的汇总敏感度为79.6%(95%CI 62.3-90.2%),特异度为88.1%(95%CI 80.1-93.1%)。
- 皮髓质期定量强化亚组(7项研究)池化敏感度85.6%(95%CI 67.8-94.4%),特异度91.7%(95%CI 76.0-97.5%),SROC曲线下面积0.894。
- T2加权成像肿瘤表现亚组(4项研究)池化敏感度89.9%(95%CI 73.0-96.7%),特异度84.9%(95%CI 69.0-93.4%)。
- T1加权同相位成像信号丢失亚组(3项研究)因明显异质性未能进行池化。
诊断标准与关键数值
- MRI鉴别乳头状肾细胞癌与其他肾脏病变:汇总敏感度79.6%(95%CI 62.3-90.2%),特异度88.1%(95%CI 80.1-93.1%)。
- 皮髓质期定量强化鉴别乳头状肾细胞癌:池化敏感度85.6%(95%CI 67.8-94.4%),特异度91.7%(95%CI 76.0-97.5%),SROC曲线下面积0.894。
- T2加权成像肿瘤表现鉴别乳头状肾细胞癌:池化敏感度89.9%(95%CI 73.0-96.7%),特异度84.9%(95%CI 69.0-93.4%)。
局限性
- T1加权同相位成像信号丢失亚组(3项研究)存在明显异质性,未能进行池化。
- 联合强化与T2信号强度特征的准确性有待进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The objective of our study was to perform a systematic review and meta-analysis of the diagnostic performance of MRI in differentiation of papillary renal cell carcinoma (RCC) from other renal masses.
MATERIALS AND METHODS: We performed searches of three electronic databases for studies that used MRI techniques to differentiate papillary RCC from other renal lesions. Methodologic quality was assessed, and diagnostic test accuracy was summarized using bivariate random-effects modeling or with construction of a summary ROC (SROC) curve.
RESULTS: Thirteen studies involving 275 papillary RCC lesions and 758 other renal masses met the inclusion criteria. Resulting summary estimates for the performance of MRI to differentiate papillary RCC from other renal lesions were a sensitivity of 79.6% (95% CI, 62.3-90.2%) and specificity of 88.1% (95% CI, 80.1-93.1%). In subgroup analysis, quantitative pooling of seven studies using enhancement in the corticomedullary phase resulted in a sensitivity of 85.6% (95% CI, 67.8-94.4%), specificity of 91.7% (95% CI, 76.0-97.5%), and area under the SROC curve of 0.894. Four studies used tumor appearance on T2-weighted imaging to detect papillary RCC, and results showed a pooled sensitivity of 89.9% (95% CI, 73.0-96.7%) and specificity of 84.9% (95% CI, 69.0-93.4%). Three studies used signal loss on T1-weighted in-phase imaging to detect papillary RCC but marked heterogeneity precluded pooling.
CONCLUSION: Meta-analysis supports moderate sensitivity and excellent specificity of quantitative enhancement in the corticomedullary phase for differentiating papillary RCC from other tumors. The accuracy of combining enhancement and T2 signal-intensity characteristics merits further evaluation as a potential aid for management decisions.
引用
- Chiarello MA, Mali RD, Kang SK, et al. Diagnostic Accuracy of MRI for Detection of Papillary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2018. PMID: 30063398. doi:10.2214/AJR.17.19462
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。